Cogent Biosciences, Inc.
COGTFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Cogent Biosciences, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Cogent Biosciences, Inc. — 10-K filed Mar 26, 2020
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 8 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 11, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 2026-03-31 | 2,113,551 | $81.4M | SEC filing |
| EverSource Wealth Advisors, LLC | 2026-03-31 | 1,611 | $62K | SEC filing |
| Saturn V Capital Management LP | 2026-03-31 | 626,635 | $24.1M | SEC filing |
| AMERIPRISE FINANCIAL INC | 2026-03-31 | 252,114 | $9.7M | SEC filing |
| NISA INVESTMENT ADVISORS, LLC | 2026-03-31 | 5,815 | $224K | SEC filing |
| Legal & General Group Plc | 2026-03-31 | 81,243 | $3.13M | SEC filing |
| Atom Investors LP | 2026-03-31 | 87,676 | $3.37M | SEC filing |
| ORBIMED ADVISORS LLC | 2026-03-31 | 322,100 | $12.4M | SEC filing |
| FOX RUN MANAGEMENT, L.L.C. | 2026-03-31 | 5,798 | $205K | SEC filing |
| IFP Advisors, Inc | 2026-03-31 | 2,224 | $85.6K | SEC filing |
| Pier Capital, LLC | 2026-03-31 | 101,304 | $3.9M | SEC filing |
| Pinnacle Wealth Planning Services, Inc. | 2026-03-31 | 141 | $5.43K | SEC filing |
| Y-Intercept (Hong Kong) Ltd | 2026-03-31 | 34,759 | $1.34M | SEC filing |
| EntryPoint Capital, LLC | 2026-03-31 | 11,123 | $428K | SEC filing |
| BOOTHBAY FUND MANAGEMENT, LLC | 2026-03-31 | 122,228 | $4.7M | SEC filing |
| Vestal Point Capital, LP | 2026-03-31 | 1,230,888 | $47.4M | SEC filing |
| NATIXIS | 2026-03-31 | 41,536 | $1.6M | SEC filing |
| PERCEPTIVE ADVISORS LLC | 2026-03-31 | 121,082 | $4.66M | SEC filing |
| Fisher Asset Management, LLC | 2026-03-31 | 167,412 | $6.44M | SEC filing |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 2026-03-31 | 13,784 | $531K | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Cogent Biosciences, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-03-31 · Fairmount Funds Management LLC: Larger than all 30 other insider sales of Common Stock on file. SEC filing
- 2026-01-22 · Fairmount Funds Management LLC: Larger than 29 of the 30 other insider sales of Common Stock on file. SEC filing
- 2020-04-29 · CAMPANA DARIO: Larger than 27 of the 30 other insider sales of Common Stock on file. SEC filing
- 2020-04-09 · CAMPANA DARIO: Larger than 28 of the 30 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-03-31 | Fairmount Funds Management LLC · Director | Common Stock | S — Open market or private sale | −7,000,000 | 34.66 | SEC filing |
| 2026-01-22 | Fairmount Funds Management LLC · Director | Common Stock | S — Open market or private sale | −3,500,000 | 36.40 | SEC filing |
| 2025-12-26 | Robinson John Edward · Chief Scientific Officer | Common Stock | S — Open market or private sale | −90,000 | 38.74 | SEC filing |
| 2025-12-26 | Green John L. · Chief Financial Officer | Common Stock | S — Open market or private sale | −77,000 | 38.68 | SEC filing |
| 2025-12-26 | Kearns Evan · Chief Legal Officer | Common Stock | S — Open market or private sale | −65,000 | 38.70 | SEC filing |
| 2025-12-26 | Sachs Jessica · Chief Medical Officer | Common Stock | S — Open market or private sale | −82,642 | 38.70 | SEC filing |
| 2025-07-10 | Fairmount Funds Management LLC · Director | Common Stock | P — Open market or private purchase | +2,777,777 | 9.00 | SEC filing |
| 2025-01-14 | Pinnow Cole · Chief Commercial Officer | Common Stock | P — Open market or private purchase | +43,750 | 7.60 | SEC filing |
Showing 8 of 19 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-09 | Shegog Todd · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,901 | SEC filing |
| 2026-06-09 | Harwin Peter Evan · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,901 | SEC filing |
| 2026-06-09 | Ros Matthew · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,901 | SEC filing |
| 2026-06-09 | CAIN CHRISTOPHER W. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,901 | SEC filing |
| 2026-06-09 | Ferrante Karen Jean · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,901 | SEC filing |
| 2026-06-09 | Morris Arlene · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,901 | SEC filing |
| 2026-05-19 | Robbins Andrew R · President and CEO | Common Stock | G — Bona fide gift | −160,000 | SEC filing |
| 2026-05-19 | Robbins Andrew R · President and CEO | Common Stock | G — Bona fide gift | +160,000 | SEC filing |
Showing 8 of 28 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2024-03-28 | Fairmount Funds Management LLC · Director | Common Stock | J — Other acquisition or disposition | −286,851 | SEC filing |
| 2024-03-28 | Fairmount Funds Management LLC · Director | Common Stock | J — Other acquisition or disposition | +286,851 | SEC filing |
| 2024-03-28 | Fairmount Funds Management LLC · Director | Series A Convertible Preferred Stock | J — Other acquisition or disposition | −11,914 | SEC filing |
| 2024-03-28 | Fairmount Funds Management LLC · Director | Series A Convertible Preferred Stock | J — Other acquisition or disposition | +11,914 | SEC filing |
| 2020-07-06 | Fairmount Funds Management LLC · 10% owner | Series A Convertible Preferred Stock | J — Other acquisition or disposition | +8,222 | SEC filing |
| 2020-07-06 | Fairmount Funds Management LLC · 10% owner | Series A Convertible Preferred Stock | J — Other acquisition or disposition | +36,465 | SEC filing |
| 2020-07-06 | Fairmount Funds Management LLC · 10% owner | Common Stock | J — Other acquisition or disposition | +5,088,497 | SEC filing |
| 2020-07-06 | Fairmount Funds Management LLC · 10% owner | Common Stock | J — Other acquisition or disposition | +1,147,406 | SEC filing |
Showing 8 of 8 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.